Similar articles

• [Therapeutic strategy in myasthenia gravis].

  Tranchant C. Tranchant C. Rev Neurol (Paris). 2009 Feb;165(2):149-54. doi: 10.1016/j.neurol.2009.01.005. Rev Neurol (Paris). 2009. PMID: 19233080 Review. French.
• Autoimmune aspects of myasthenia gravis.

  Lisak RP, Levinson AI, Zweiman B. Lisak RP, et al. Concepts Immunopathol. 1985;2:65-101. Concepts Immunopathol. 1985. PMID: 3916415 Review. No abstract available.
• Beneficial effect of tacrolimus on myasthenia gravis with thymoma.

  Mitsui T, Kunishige M, Ichimiya M, Shichijo K, Endo I, Matsumoto T. Mitsui T, et al. Neurologist. 2007 Mar;13(2):83-6. doi: 10.1097/01.nrl.0000256352.77668.ef. Neurologist. 2007. PMID: 17351528 Clinical Trial.
• [Aplastic anemia in thymoma].

  Seewann HL, Wascher H, Wagner K, Fladerer H. Seewann HL, et al. Med Klin. 1972 Nov 10;67(45):1477-9. Med Klin. 1972. PMID: 4637697 German. No abstract available.
• Immunopharmacological treatment in myasthenia gravis.

  Nyberg-Hansen R, Gjerstad L. Nyberg-Hansen R, et al. Transplant Proc. 1988 Jun;20(3 Suppl 4):201-10. Transplant Proc. 1988. PMID: 3289206 Review. No abstract available.